Genentech's Avastin cancer drug appears to treat age-related macular degeneration as safely as Genentech's drug Lucentis, which is approved for that condition and costs significantly more, a new analysis says. The findings, published Monday, are ... San Francisco Chronicle, 4 days ago
Costly Genentech drug as safe as cheap Genentech drug, study finds - San Francisco Chronicle, 4 days ago
Roche's Genentech triggers its PhIII program for blockbuster AMD contender - FierceBiotech, 5 days ago
SPONSOR Webinar: Five Questions To Ask Before Selecting A Raw Materials Supplier Join David Radspinner, Ph.D., General Manager, HyClone Cell Culture Products, GE Healthcare, on September 18, 2014, for a free webinar on raw ...Pharmaceutical Online, 1 week ago
Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group ...Scottrade, 2 days ago The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023 Franklin Credit Management Corporation, 2 days ago At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients Scottrade, 2 days ago Eylea, Lucentis Equally Likely to Be Covered on Commercial and Medicare Advantage Plans for Wet AMD P&T Community, 1 day ago
On July 13, 2014, Exelixis announced positive top-line results from coBRIM after being informed by Genentech, a member of the Roche Group and Exelixis collaborator, that coBRIM met its primary endpoint, delivering a ...Morningstar.com, 4 days ago Exelixis to present cobimetinib phase 3 coBRIM results at ESMO 2014 Congress PharmaBiz, 3 days ago Exelixis, Inc. Announces Cobimetinib Phase 3 coBRIM Results To Be Presented At 2014 Congress BioSpace, 3 days ago EXELIXIS : Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress 4 Traders, 4 days ago
Site-Specific Trastuzumab Maytansinoid AntibodyDrug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080,Journal of Medicinal Chemistry, 2 days ago
Researchers from Genentech, Inc. Describe Findings in Immunoglobulins (Combined Administration of RG7652, a Recombinant Human Monoclonal Antibody...
Researchers from Genentech, Inc. Describe Findings in Immunoglobulins ( Combined Administration of RG7652 , a Recombinant Human Monoclonal Antibody Against PCSK9, and Atorvastatin Does Not Result in Reduction of Immune Function) (Combined ...) By ...4 Traders, 3 days ago Investigators at Genentech, Inc. Describe Findings in Apoptosis (E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis)... 4 Traders, 3 days ago New Findings in Breast Cancer Described from Genentech, Inc. (Changes in PIK3CA mutation status are not associated with recurrence, metastatic... 4 Traders, 1 week ago
Studies from Genentech, Inc. Reveal New Findings on Human Heredity (Using Gene Expression to Improve the Power of Genome-Wide Association Analysis)...
Studies from Genentech, Inc. Reveal New Findings on Human Heredity (Using Gene Expression to Improve the Power of Genome-Wide Association Analysis) (Using Gene Expression to Improve the Power of Genome-Wide Association Analysis) By a News ...4 Traders, 3 days ago Researchers from Genentech, Inc. Detail New Studies and Findings in the Area of Apoptosis (Using RNAi screening technologies to interrogate the... 4 Traders, 3 days ago Researchers from Genentech Report Recent Findings in Apoptosis (Apoptosis initiation through the cell-extrinsic pathway) (Apoptosis initiation... 4 Traders, 3 days ago
Reports from Genentech, Inc. Add New Data to Findings in Enzyme Research (Complementary methods for the identification of substrates of proteolysis)...4 Traders, 3 days ago Researchers from Genentech, Inc. Report Recent Findings in Environmental Toxicology (Rational Selection Of Alternative, Environmentally Compatible... 4 Traders, 1 week ago SYSTEM RESEARCH : Findings from Genentech, Inc. Has Provided New Data on Neuroscience (Activity-Induced Nr4a1 Regulates Spine Density and Distribution Pattern of... 4 Traders, 1 week ago
By Bio-IT World Staff September 15, 2014 | Like a lot of large pharma and biotech companies adapting to the era of big data, Genentech has lately found that its preclinical models, the animals and cell lines in its inventory, don't scale up as ...Bio-IT World, 5 days ago
Xenon Pharmaceuticals has gone 8 long years since its last equity raise, relying on a slate of partnerships with some of the biggest names in the business to fund its work. And now it's set out to test the fall biotech IPO market with a $52 million ...FierceBiotech, 1 week ago
on your WebpageAdd Widget >Get your members hooked!